Weaverly Colleen Lee

All Publications

• Protocol for detection of ferroptosis in cultured cells. STAR protocols Murray, M. B., Leak, L. B., Lee, W. C., Dixon, S. J. 2023; 4 (3): 102457

  Abstract

  Mammalian cells can die by apoptosis or by one of several non-apoptotic mechanisms, such as ferroptosis. Here, we present a protocol to distinguish ferroptosis from other cell death mechanisms in cultured cells. We describe steps for seeding cells, administering mechanism-specific cell death inducers and inhibitors, and measuring cell death and viability. We then detail the use of molecular markers to verify mechanisms of cell death. This protocol can be used to identify and distinguish ferroptosis in 2D and 3D cultures. For complete details on the use and execution of this protocol, please refer to Ko, et al. (2019),1 Magtanong, et al. (2022),2 and Armenta, et al. (2022).3.

  View details for DOI 10.1016/j.xpro.2023.102457

  View details for PubMedID 37556320

• TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A NATURE Brown, A., Wilkins, O. G., Keuss, M. J., Hill, S. E., Zanovello, M., Lee, W., Bampton, A., Lee, F. Y., Masino, L., Qi, Y. A., Bryce-Smith, S., Gatt, A., Hallegger, M., Fagegaltier, D., Phatnani, H., Newcombe, J., Gustavsson, E. K., Seddighi, S., Reyes, J. F., Coon, S. L., Ramos, D., Schiavo, G., Fisher, E. C., Raj, T., Secrier, M., Lashley, T., Ule, J., Buratti, E., Humphrey, J., Ward, M. E., Fratta, P., NYGC ALS Consortium 2022; 603 (7899): 131-+

  Abstract

  Variants of UNC13A, a critical gene for synapse function, increase the risk of amyotrophic lateral sclerosis and frontotemporal dementia1-3, two related neurodegenerative diseases defined by mislocalization of the RNA-binding protein TDP-434,5. Here we show that TDP-43 depletion induces robust inclusion of a cryptic exon in UNC13A, resulting in nonsense-mediated decay and loss of UNC13A protein. Two common intronic UNC13A polymorphisms strongly associated with amyotrophic lateral sclerosis and frontotemporal dementia risk overlap with TDP-43 binding sites. These polymorphisms potentiate cryptic exon inclusion, both in cultured cells and in brains and spinal cords from patients with these conditions. Our findings, which demonstrate a genetic link between loss of nuclear TDP-43 function and disease, reveal the mechanism by which UNC13A variants exacerbate the effects of decreased TDP-43 function. They further provide a promising therapeutic target for TDP-43 proteinopathies.

  View details for DOI 10.1038/s41586-022-04436-3

  View details for Web of Science ID 000760257200005

  View details for PubMedID 35197628

  View details for PubMedCentralID PMC8891020

• NMJ-Analyser identifies subtle early changes in mouse models of neuromuscular disease SCIENTIFIC REPORTS Maza, A., Jarvis, S., Lee, W., Cunningham, T. J., Schiavo, G., Secrier, M., Fratta, P., Sleigh, J. N., Fisher, E. C., Sudre, C. H. 2021; 11 (1): 12251

  Abstract

  The neuromuscular junction (NMJ) is the peripheral synapse formed between a motor neuron axon terminal and a muscle fibre. NMJs are thought to be the primary site of peripheral pathology in many neuromuscular diseases, but innervation/denervation status is often assessed qualitatively with poor systematic criteria across studies, and separately from 3D morphological structure. Here, we describe the development of 'NMJ-Analyser', to comprehensively screen the morphology of NMJs and their corresponding innervation status automatically. NMJ-Analyser generates 29 biologically relevant features to quantitatively define healthy and aberrant neuromuscular synapses and applies machine learning to diagnose NMJ degeneration. We validated this framework in longitudinal analyses of wildtype mice, as well as in four different neuromuscular disease models: three for amyotrophic lateral sclerosis (ALS) and one for peripheral neuropathy. We showed that structural changes at the NMJ initially occur in the nerve terminal of mutant TDP43 and FUS ALS models. Using a machine learning algorithm, healthy and aberrant neuromuscular synapses are identified with 95% accuracy, with 88% sensitivity and 97% specificity. Our results validate NMJ-Analyser as a robust platform for systematic and structural screening of NMJs, and pave the way for transferrable, and cross-comparison and high-throughput studies in neuromuscular diseases.

  View details for DOI 10.1038/s41598-021-91094-6

  View details for Web of Science ID 000663785600001

  View details for PubMedID 34112844

  View details for PubMedCentralID PMC8192785

• A novel knockout mouse for the small EDRK-rich factor 2 (Serf2) showing developmental and other deficits MAMMALIAN GENOME Cleverley, K., Lee, W., Mumford, P., Collins, T., Rickman, M., Cunningham, T. J., Cleak, J., Mianne, J., Szoke-Kovacs, Z., Stewart, M., Teboul, L., Maduro, C., Wells, S., Wiseman, F. K., Fisher, E. C. 2021; 32 (2): 94-103

  Abstract

  The small EDRK-rich factor 2 (SERF2) is a highly conserved protein that modifies amyloid fibre assembly in vitro and promotes protein misfolding. However, the role of SERF2 in regulating age-related proteotoxicity remains largely unexplored due to a lack of in vivo models. Here, we report the generation of Serf2 knockout mice using an ES cell targeting approach, with Serf2 knockout alleles being bred onto different defined genetic backgrounds. We highlight phenotyping data from heterozygous Serf2+/- mice, including unexpected male-specific phenotypes in startle response and pre-pulse inhibition. We report embryonic lethality in Serf2-/- null animals when bred onto a C57BL/6 N background. However, homozygous null animals were viable on a mixed genetic background and, remarkably, developed without obvious abnormalities. The Serf2 knockout mice provide a powerful tool to further investigate the role of SERF2 protein in previously unexplored pathophysiological pathways in the context of a whole organism.

  View details for DOI 10.1007/s00335-021-09864-6

  View details for Web of Science ID 000628461600001

  View details for PubMedID 33713180

  View details for PubMedCentralID PMC8012326